LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 1256 | 5013 | 0.2506 | -0.0150 |
MDA-MB-231 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4858 | 5013 | 0.9690 | 0.9580 |
MDA-MB-231 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4962 | 5013 | 0.9899 | 0.9863 |
MDA-MB-231 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4853 | 5013 | 0.9681 | 0.9567 |
MDA-MB-231 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4473 | 5013 | 0.8923 | 0.8542 |
MDA-MB-231 | R406 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4938 | 5013 | 0.9849 | 0.9796 |
MDA-MB-231 | Pictilisib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4066 | 5013 | 0.8110 | 0.7440 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5117 | 5013 | 1.0207 | 1.0280 |
MDA-MB-231 | Geldanamycin | 0.04 | uM | LJP5 | 72 | hr | 1311 | 3731 | 5013 | 0.7443 | 0.6536 |
MDA-MB-231 | Geldanamycin | 0.04 | uM | LJP6 | 72 | hr | 1311 | 3430 | 5013 | 0.6842 | 0.5723 |
MDA-MB-231 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5134 | 5013 | 1.0240 | 1.0325 |
MDA-MB-231 | GSK1059615 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5133 | 5013 | 1.0240 | 1.0325 |
MDA-MB-231 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4224 | 5013 | 0.8425 | 0.7867 |
MDA-MB-231 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 3047 | 5013 | 0.6079 | 0.4690 |
MDA-MB-231 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4763 | 5013 | 0.9500 | 0.9323 |
MDA-MB-231 | GW843682X | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4692 | 5013 | 0.9359 | 0.9132 |
MDA-MB-231 | HG-5-113-01 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4993 | 5013 | 0.9960 | 0.9946 |
MDA-MB-231 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4077 | 5013 | 0.8133 | 0.7471 |
MDA-MB-231 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4853 | 5013 | 0.9680 | 0.9566 |
MDA-MB-231 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4136 | 5013 | 0.8250 | 0.7630 |
MDA-MB-231 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4188 | 5013 | 0.8355 | 0.7772 |
MDA-MB-231 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4495 | 5013 | 0.8967 | 0.8601 |
MDA-MB-231 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4869 | 5013 | 0.9712 | 0.9610 |
MDA-MB-231 | Linifanib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5333 | 5013 | 1.0639 | 1.0865 |
MDA-MB-231 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4312 | 5013 | 0.8601 | 0.8106 |